Loading...

Steven Batki, MD

TitleProfessor
SchoolUCSF School of Medicine
DepartmentPsychiatry
Address4150 Clement Street
San Francisco CA 94121
Phone415-221-4810
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoResidency School of Medicine

    Collapse Overview 
    Collapse Overview
    Steven L. Batki, M.D. is Professor of Psychiatry, in Residence, at the University of California, San Francisco (UCSF) School of Medicine and Chief of the Substance Abuse Programs and Director of the Addiction Psychiatry Research Program at the San Francisco VA Medical Center (SFVAMC), where he also directs the UCSF Addiction Psychiatry Fellowship Program. Dr. Batki is engaged in addiction research, training, and clinical services.

    Dr. Batki’s research and clinical interests include pharmacologic treatment for addiction to alcohol, opioids, and stimulants. His work focuses on psychiatric and medical disorders that co-occur with addiction, such as such as PTSD, traumatic brain injury (TBI), schizophrenia, and HIV/HCV. He has published extensively on clinical research in addiction and co-occurring disorders. He chaired the SAMSHA CSAT Treatment Improvement Protocol No. 37, Substance Abuse Treatment for Persons with HIV/AIDS, and Treatment Improvement Protocol No. 43, Medication-Assisted Treatment for Opioid Dependence.

    Dr. Batki's current research is supported by the Department of Defense and NIDA. His DoD projects are examining the effectiveness of pharmacotherapy for alcohol use disorders in veterans with posttraumatic stress disorder (PTSD) as well as in veterans with mild traumatic brain injury (TBI). Dr. Batki is also conducting NIDA-funded research on the pharmacotherapy of methamphetamine dependence. Recently completed NIDA and NIAAA work has included the study of hepatitis C treatment in injection drug users and the pharmacological treatment of alcohol dependence in schizophrenia.


    Collapse Research 
    Collapse Research Activities and Funding
    Mirtazapine for the treatment of methamphetamine dependence among MSM with high-r
    NIH/NIDA R01DA034527Feb 1, 2013 - Jan 31, 2018
    Role: Principal Investigator
    Naltrexone for the treatment of Actively-Using Met-Dependent MSM with High-Risk B
    NIH/NIDA R01DA031678Jun 1, 2011 - Jan 31, 2017
    Role: Co-Principal Investigator
    Improving Hepatitis C Treatment in Injection Drug Users
    NIH/NIDA R01DA016764Sep 26, 2003 - Jun 30, 2010
    Role: Principal Investigator
    Naltrexone Treatment of Alcohol Abuse in Schizophrenia
    NIH/NIAAA R01AA013655Apr 1, 2003 - Mar 31, 2009
    Role: Principal Investigator
    PHARMACOTHERAPY OF METHAMPHETAMINE DEPENDENCE
    NIH/NIDA R01DA011397Feb 20, 1998 - Dec 31, 2002
    Role: Principal Investigator
    Treatment for Complex Patients: Continuing and Extended Care
    NIH/NIDA P50DA009253Sep 29, 1994 - May 31, 2015
    Role: Co-Investigator
    TUBERCULOSIS CHEMOPROPHYLAXIS IN INJECTION DRUG USERS
    NIH/NIDA R01DA008526Aug 1, 1994 - Jun 30, 1998
    Role: Principal Investigator
    DRUG DEPENDENCE CLINICAL RESEARCH PROGRAM
    NIH/NIDA P50DA001696Feb 1, 1978 - Aug 31, 2000
    Role: Co-Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000083Oct 1, 1974 - Nov 30, 2007
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Turner CM, Coffin P, Santos D, Huffaker S, Matheson T, Euren J, DeMartini A, Rowe C, Batki S, Santos GM. Race/ethnicity, education, and age are associated with engagement in ecological momentary assessment text messaging among substance-using MSM in San Francisco. J Subst Abuse Treat. 2017 Apr; 75:43-48. PMID: 28237053.
      View in: PubMed
    2. Heinz AJ, Pennington DL, Cohen N, Schmeling B, Lasher BA, Schrodek E, Batki S. Relations Between Cognitive Functioning and Alcohol Use, Craving, and Post-Traumatic Stress: An Examination Among Trauma-Exposed Military Veterans With Alcohol Use Disorder. Mil Med. 2016 Jul; 181(7):663-71. PMID: 27391620.
      View in: PubMed
    3. Woolley JD, Arcuni PA, Stauffer CS, Fulford D, Carson DS, Batki S, Vinogradov S. The effects of intranasal oxytocin in opioid-dependent individuals and healthy control subjects: a pilot study. Psychopharmacology (Berl). 2016 Jul; 233(13):2571-80. PMID: 27137199.
      View in: PubMed
    4. Santos GM, Coffin P, Santos D, Huffaker S, Matheson T, Euren J, DeMartini A, Rowe C, Hahn JA, Vlahov D, Vittinghoff E, Batki S. Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex with Men. J Acquir Immune Defic Syndr. 2016 May 1; 72(1):21-30. PMID: 26674372.
      View in: PubMed
    5. Seal KH, Maguen S, Bertenthal D, Batki S, Striebel J, Stein MB, Madden E, Neylan TC. Observational evidence for buprenorphine's impact on posttraumatic stress symptoms in veterans with chronic pain and opioid use disorder. J Clin Psychiatry. 2016 Mar 1. PMID: 27035058.
      View in: PubMed
    6. Batki S. What is the right pharmacotherapy for alcohol use disorder in patients with schizophrenia? J Clin Psychiatry. 2015 Oct; 76(10):e1336-7. PMID: 26528663.
      View in: PubMed
    7. Rubinsky AD, Chen C, Batki S, Williams EC, Harris AH. Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual diagnoses. J Psychiatr Res. 2015 Oct; 69:150-7. PMID: 26343607.
      View in: PubMed
    8. Kaplan KA, McQuaid J, Batki S, Rosenlicht N. Behavioral treatment of insomnia in early recovery. J Addict Med. 2014 Nov-Dec; 8(6):395-8. PMID: 25369939.
      View in: PubMed
    9. Pennington DL, Abé C, Batki S, Johannes Meyerhoff D. A preliminary examination of cortical neurotransmitter levels associated with heavy drinking in posttraumatic stress disorder. Psychiatry Res. 2014 Dec 30; 224(3):281-7. PMID: 25444536; PMCID: PMC4254450 [Available on 12/30/15].
    10. Batki S, Pennington DL, Lasher B, Neylan TC, Metzler T, Waldrop A, Delucchi K, Herbst E. Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial. Alcohol Clin Exp Res. 2014 Aug; 38(8):2169-77. PMID: 25092377; PMCID: PMC4146719.
    11. Batki S, Pennington DL. Toward personalized medicine in the pharmacotherapy of alcohol use disorder: targeting patient genes and patient goals. Am J Psychiatry. 2014 Apr; 171(4):391-4. PMID: 24687193.
      View in: PubMed
    12. Kalapatapu RK, Ho J, Cai X, Vinogradov S, Batki S, Mohr DC. Cognitive-behavioral therapy in depressed primary care patients with co-occurring problematic alcohol use: effect of telephone-administered vs. face-to-face treatment-a secondary analysis. J Psychoactive Drugs. 2014 Apr-Jun; 46(2):85-92. PMID: 25052784; PMCID: PMC4110640.
    13. Kalapatapu RK, Delucchi KL, Lasher BA, Vinogradov S, Batki S. Alcohol use biomarkers predicting cognitive performance: a secondary analysis in veterans with alcohol dependence and posttraumatic stress disorder. Mil Med. 2013 Sep; 178(9):974-80. PMID: 24005546; PMCID: PMC3815580.
    14. Meszaros ZS, Abdul-Malak Y, Dimmock JA, Wang D, Ajagbe TO, Batki S. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial. J Clin Psychopharmacol. 2013 Apr; 33(2):243-7. PMID: 23422399.
      View in: PubMed
    15. Kalapatapu RK, Lewis DF, Vinogradov S, Batki S, Winhusen T. Relationship of age to impulsivity and decision making: a baseline secondary analysis of a behavioral treatment study in stimulant use disorders. J Addict Dis. 2013; 32(2):206-16. PMID: 23815427; PMCID: PMC3703837.
    16. Wamsley MA, Julian KA, O'Sullivan P, McCance-Katz EF, Batki S, Satre DD, Satterfield J. Team-based learning exercise efficiently teaches brief intervention skills to medicine residents. Subst Abus. 2013; 34(4):344-9. PMID: 24159904.
      View in: PubMed
    17. Satterfield JM, O'Sullivan P, Satre DD, Tsoh JY, Batki S, Julian K, McCance-Katz EF, Wamsley M. Using standardized patients to evaluate screening, brief intervention, and referral to treatment (SBIRT) knowledge and skill acquisition for internal medicine residents. Subst Abus. 2012; 33(3):303-7. PMID: 22738010.
      View in: PubMed
    18. Meszaros ZS, Dimmock JA, Ploutz-Snyder R, Chauhan SV, Abdul-Malak Y, Middleton FA, Batki S. Accuracy of self-reported medical problems in patients with alcohol dependence and co-occurring schizophrenia or schizoaffective disorder. Schizophr Res. 2011 Nov; 132(2-3):190-3. PMID: 21852074; PMCID: PMC3195925.
    19. Meszaros ZS, Dimmock JA, Ploutz-Snyder RJ, Abdul-Malak Y, Leontieva L, Canfield K, Batki S. Predictors of smoking severity in patients with schizophrenia and alcohol use disorders. Am J Addict. 2011 Sep-Oct; 20(5):462-7. PMID: 21838846; PMCID: PMC3156655.
    20. Batki S, Canfield KM, Ploutz-Snyder R. Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: effects on eligibility for hepatitis C treatment. Am J Addict. 2011 Jul-Aug; 20(4):312-8. PMID: 21679262.
      View in: PubMed
    21. Batki S, Canfield KM, Smyth E, Ploutz-Snyder R, Levine RA. Hepatitis C treatment eligibility and comorbid medical illness in methadone maintenance (MMT) and non-MMT patients: a case-control study. J Addict Dis. 2010 Jul; 29(3):359-69. PMID: 20635285.
      View in: PubMed
    22. Funderburk JS, Sugarman DE, Maisto SA, Ouimette P, Schohn M, Lantinga L, Wray L, Batki S, Nelson B, Coolhart D, Strutynski K. The description and evaluation of the implementation of an integrated healthcare model. Fam Syst Health. 2010 Jun; 28(2):146-60. PMID: 20695672.
      View in: PubMed
    23. Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki S. Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol. 2010 Jun; 69(6):578-92. PMID: 20565449; PMCID: PMC2883750.
    24. Raza S, Siddiqui UA, Megna JL, Schwartz TL, Batki S. Pregabalin treatment of anxiety in patients with substance use disorders. Ann Pharmacother. 2010 May; 44(5):937-8. PMID: 20388860.
      View in: PubMed
    25. Canfield KM, Smyth E, Batki S. Methadone maintenance patients' knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection. Subst Use Misuse. 2010 Mar; 45(4):496-514. PMID: 20141461.
      View in: PubMed
    26. Batki S, Canfield KM, Smyth E, Ploutz-Snyder R. Health-related quality of life in methadone maintenance patients with untreated hepatitis C virus infection. Drug Alcohol Depend. 2009 May 1; 101(3):176-82. PMID: 19233573.
      View in: PubMed
    27. Leontieva L, Dimmock J, Cavallerano M, DeRycke S, Meszaros Z, Carey K, Ploutz-Snyder R, Batki S. Patient and provider attitudes towards monitored naltrexone treatment of alcohol dependence in schizophrenia. Am J Drug Alcohol Abuse. 2009; 35(5):273-8. PMID: 19591067.
      View in: PubMed
    28. Batki S, Meszaros ZS, Strutynski K, Dimmock JA, Leontieva L, Ploutz-Snyder R, Canfield K, Drayer RA. Medical comorbidity in patients with schizophrenia and alcohol dependence. Schizophr Res. 2009 Feb; 107(2-3):139-46. PMID: 19022627; PMCID: PMC2649875.
    29. Batki S, Leontieva L, Dimmock JA, Ploutz-Snyder R. Negative symptoms are associated with less alcohol use, craving, and "high" in alcohol dependent patients with schizophrenia. Schizophr Res. 2008 Oct; 105(1-3):201-7. PMID: 18701256; PMCID: PMC2582942.
    30. Gruber VA, Delucchi KL, Kielstein A, Batki S. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug Alcohol Depend. 2008 Apr 1; 94(1-3):199-206. PMID: 18243585; PMCID: PMC2821580.
    31. Leontieva L, Dimmock JA, Gately PW, Gallinger L, Ploutz-Snyder R, Batki S. Voucher-based incentives for naltrexone treatment attendance in schizophrenia and alcohol use disorders. Psychiatr Serv. 2008 Mar; 59(3):310-4. PMID: 18308913.
      View in: PubMed
    32. Smelson DA, Dixon L, Craig T, Remolina S, Batki S, Niv N, Owen R. Pharmacological treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs. 2008; 22(11):903-16. PMID: 18840032.
      View in: PubMed
    33. Batki S, Dimmock JA, Wade M, Gately PW, Cornell M, Maisto SA, Carey KB, Ploutz-Snyder R. Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders. Am J Addict. 2007 Jul-Aug; 16(4):253-9. PMID: 17661192.
      View in: PubMed
    34. Carey KB, Leontieva L, Dimmock J, Maisto SA, Batki S. Adapting Motivational Interventions for Comorbid Schizophrenia and Alcohol Use Disorders. Clin Psychol (New York). 2007 Mar; 14(1):39-57. PMID: 19081784.
      View in: PubMed
    35. Sorensen JL, Haug NA, Delucchi KL, Gruber V, Kletter E, Batki S, Tulsky JP, Barnett P, Hall S. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend. 2007 Apr 17; 88(1):54-63. PMID: 17056206; PMCID: PMC1976289.
    36. Alleyne S, Alao A, Batki S. Lamotrigine-associated rash and blood dyscrasias in a methadone-treatment patient with hepatitis C. Psychosomatics. 2006 May-Jun; 47(3):257-8. PMID: 16684944.
      View in: PubMed
    37. Manfredi L, Shupe J, Batki S. Rural jail telepsychiatry: a pilot feasibility study. Telemed J E Health. 2005 Oct; 11(5):574-7. PMID: 16250821.
      View in: PubMed
    38. Ziedonis DM, Smelson D, Rosenthal RN, Batki S, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract. 2005 Sep; 11(5):315-39. PMID: 16184072; PMCID: PMC2599914.
    39. Harris DS, Batki S, Berger SP. Fluoxetine attenuates adrenocortical but not subjective responses to cocaine cues. Am J Drug Alcohol Abuse. 2004 Nov; 30(4):765-82. PMID: 15624548.
      View in: PubMed
    40. Batki S, Harris DS. Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia. Am J Addict. 2004 Oct-Dec; 13(5):461-70. PMID: 15764424.
      View in: PubMed
    41. Escamilla MA, Batki S, Reus VI, Spesny M, Molina J, Service S, Vinogradov S, Neylan T, Mathews C, Meza L, Gallegos A, Montero AP, Cruz ML, Neuhaus J, Roche E, Smith L, Leon P, Freimer NB. Comorbidity of bipolar disorder and substance abuse in Costa Rica: pedigree- and population-based studies. J Affect Disord. 2002 Sep; 71(1-3):71-83. PMID: 12167503.
      View in: PubMed
    42. Batki S. Review: dopamine agonists are not effective for cocaine dependence. Evid Based Ment Health. 2002 Aug; 5(3):82-3. PMID: 12180450.
      View in: PubMed
    43. Batki S. Review: antidepressants are not effective for cocaine dependence. Evid Based Ment Health. 2002 Aug; 5(3):82-3. PMID: 12180449.
      View in: PubMed
    44. Ophoff RA, Escamilla MA, Service SK, Spesny M, Meshi DB, Poon W, Molina J, Fournier E, Gallegos A, Mathews C, Neylan T, Batki S, Roche E, Ramirez M, Silva S, De Mille MC, Dong P, Leon PE, Reus VI, Sandkuijl LA, Freimer NB. Genomewide linkage disequilibrium mapping of severe bipolar disorder in a population isolate. Am J Hum Genet. 2002 Sep; 71(3):565-74. PMID: 12119601; PMCID: PMC379193.
    45. Batki S, Gruber VA, Bradley JM, Bradley M, Delucchi K. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend. 2002 May 1; 66(3):283-93. PMID: 12062463.
      View in: PubMed
    46. Masson CL, Sorensen JL, Batki S, Okin R, Delucchi KL, Perlman DC. Medical service use and financial charges among opioid users at a public hospital. Drug Alcohol Depend. 2002 Mar 1; 66(1):45-50. PMID: 11850135.
      View in: PubMed
    47. Delucchi KL, Batki S, Moon J, Jacob P, Jones RT. Urine toxicology samples in cocaine treatment trials: how many need to be tested? J Addict Dis. 2002; 21(2):17-26. PMID: 11916369.
      View in: PubMed
    48. McInnes LA, Service SK, Reus VI, Barnes G, Charlat O, Jawahar S, Lewitzky S, Yang Q, Duong Q, Spesny M, Araya C, Araya X, Gallegos A, Meza L, Molina J, Ramirez R, Mendez R, Silva S, Fournier E, Batki S, Mathews CA, Neylan T, Glatt CE, Escamilla MA, Luo D, Gajiwala P, Song T, Crook S, Nguyen JB, Roche E, Meyer JM, Leon P, Sandkuijl LA, Freimer NB, Chen H. Fine-scale mapping of a locus for severe bipolar mood disorder on chromosome 18p11.3 in the Costa Rican population. Proc Natl Acad Sci U S A. 2001 Sep 25; 98(20):11485-90. PMID: 11572994; PMCID: PMC58756.
    49. Escamilla MA, McInnes LA, Service SK, Spesny M, Reus VI, Molina J, Gallegos A, Fournier E, Batki S, Neylan T, Matthews C, Vinogradov S, Roche E, Tyler DJ, Shimayoshi N, Mendez R, Ramirez R, Ramirez M, Araya C, Araya X, Leon PE, Sandkuijl LA, Freimer NB. Genome screening for linkage disequilibrium in a Costa Rican sample of patients with bipolar-I disorder: a follow-up study on chromosome 18. Am J Med Genet. 2001 Mar 8; 105(2):207-13. PMID: 11304838.
      View in: PubMed
    50. Schiller MJ, Shumway M, Batki S. Utility of routine drug screening in a psychiatric emergency setting. Psychiatr Serv. 2000 Apr; 51(4):474-8. PMID: 10737822.
      View in: PubMed
    51. Harris D, Batki S. Stimulant psychosis: symptom profile and acute clinical course. Am J Addict. 2000; 9(1):28-37. PMID: 10914291.
      View in: PubMed
    52. Schiller MJ, Shumway M, Batki S. Patterns of substance use among patients in an urban psychiatric emergency service. Psychiatr Serv. 2000 Jan; 51(1):113-5. PMID: 10647144.
      View in: PubMed
    53. Ferrando SJ, Batki S. Substance abuse and HIV infection. New Dir Ment Health Serv. 2000; (87):57-67. PMID: 11031802.
      View in: PubMed
    54. Batki S, Moon J, Delucchi K, Bradley M, Hersh D, Smolar S, Mengis M, Lefkowitz E, Sexe D, Morello L, Everhart T, Jones RT, Jacob P. Methamphetamine quantitative urine concentrations during a controlled trial of fluoxetine treatment. Preliminary analysis. Ann N Y Acad Sci. 2000; 909:260-3. PMID: 10911936.
      View in: PubMed
    55. Panganiban K, Jacob P, Everhart ET, Tisdale EC, Batki S, Mendelson JE, Jones RT. Sulfonium salts as derivatizing agents. 3. Quantitation of the cocaine metabolite benzoylecgonine in urine using gas chromatography with ion-pair extraction/on-column alkylation. J Anal Toxicol. 1999 Nov-Dec; 23(7):581-5. PMID: 10595843.
      View in: PubMed
    56. Escamilla MA, McInnes LA, Spesny M, Reus VI, Service SK, Shimayoshi N, Tyler DJ, Silva S, Molina J, Gallegos A, Meza L, Cruz ML, Batki S, Vinogradov S, Neylan T, Nguyen JB, Fournier E, Araya C, Barondes SH, Leon P, Sandkuijl LA, Freimer NB. Assessing the feasibility of linkage disequilibrium methods for mapping complex traits: an initial screen for bipolar disorder loci on chromosome 18. Am J Hum Genet. 1999 Jun; 64(6):1670-8. PMID: 10330354; PMCID: PMC1377910.
    57. Sorensen JL, Mascovich A, Wall TL, DePhilippis D, Batki S, Chesney M. Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care. 1998 Jun; 10(3):297-312. PMID: 9828973.
      View in: PubMed
    58. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998 Apr; 93(4):475-86. PMID: 9684386.
      View in: PubMed
    59. Mendelson J, Jones RT, Welm S, Brown J, Batki S. Buprenorphine and naloxone interactions in methadone maintenance patients. Biol Psychiatry. 1997 Jun 1; 41(11):1095-101. PMID: 9146820.
      View in: PubMed
    60. Delucchi KL, Jones RT, Batki S. Measurement properties of quantitative urine benzoylecgonine in clinical trials research. Addiction. 1997 Mar; 92(3):297-302. PMID: 9219391.
      View in: PubMed
    61. McInnes LA, Escamilla MA, Service SK, Reus VI, Leon P, Silva S, Rojas E, Spesny M, Baharloo S, Blankenship K, Peterson A, Tyler D, Shimayoshi N, Tobey C, Batki S, Vinogradov S, Meza L, Gallegos A, Fournier E, Smith LB, Barondes SH, Sandkuijl LA, Freimer NB. A complete genome screen for genes predisposing to severe bipolar disorder in two Costa Rican pedigrees. Proc Natl Acad Sci U S A. 1996 Nov 12; 93(23):13060-5. PMID: 8917544; PMCID: PMC24046.
    62. Ferrando SJ, Wall TL, Batki S, Sorensen JL. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. Am J Drug Alcohol Abuse. 1996 Nov; 22(4):475-87. PMID: 8911586.
      View in: PubMed
    63. Batki S, Washburn AM, Delucchi K, Jones RT. A controlled trial of fluoxetine in crack cocaine dependence. Drug Alcohol Depend. 1996 Jun; 41(2):137-42. PMID: 8809502.
      View in: PubMed
    64. Freimer NB, Reus VI, Escamilla M, Spesny M, Smith L, Service S, Gallegos A, Meza L, Batki S, Vinogradov S, Leon P, Sandkuijl LA. An approach to investigating linkage for bipolar disorder using large Costa Rican pedigrees. Am J Med Genet. 1996 May 31; 67(3):254-63. PMID: 8725744.
      View in: PubMed
    65. Freimer NB, Reus VI, Escamilla MA, McInnes LA, Spesny M, Leon P, Service SK, Smith LB, Silva S, Rojas E, Gallegos A, Meza L, Fournier E, Baharloo S, Blankenship K, Tyler DJ, Batki S, Vinogradov S, Weissenbach J, Barondes SH, Sandkuijl LA. Genetic mapping using haplotype, association and linkage methods suggests a locus for severe bipolar disorder (BPI) at 18q22-q23. Nat Genet. 1996 Apr; 12(4):436-41. PMID: 8630501.
      View in: PubMed
    66. Herbst MD, Batki S, Manfredi LB, Jones T. Treatment outcomes for methadone clients receiving lump-sum payments at initiation of disability benefits. Psychiatr Serv. 1996 Feb; 47(2):119-20, 142. PMID: 8825244.
      View in: PubMed
    67. Wall TL, Sorensen JL, Batki S, Delucchi KL, London JA, Chesney MA. Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. Drug Alcohol Depend. 1995 Mar; 37(3):261-9. PMID: 7796721.
      View in: PubMed
    68. Batki S, Manfredi LB, Jacob P, Jones RT. Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations. J Clin Psychopharmacol. 1993 Aug; 13(4):243-50. PMID: 8376611.
      View in: PubMed
    69. Ferrando SJ, Batki S. HIV-infected intravenous drug users in methadone maintenance treatment: clinical problems and their management. J Psychoactive Drugs. 1991 Apr-Jun; 23(2):217-24. PMID: 1662716.
      View in: PubMed
    70. Batki S. Buspirone in drug users with AIDS or AIDS-related complex. J Clin Psychopharmacol. 1990 Jun; 10(3 Suppl):111S-115S. PMID: 2376626.
      View in: PubMed
    71. Batki S. Drug abuse, psychiatric disorders, and AIDS. Dual and triple diagnosis. West J Med. 1990 May; 152(5):547-52. PMID: 2190423; PMCID: PMC1002409.
    72. Batki S, Manfredi LB, Sorensen JL, Jacob P, Dumontet R, Jones RT. Fluoxetine for cocaine abuse in methadone patients: preliminary findings. NIDA Res Monogr. 1990; 105:516-7. PMID: 1876106.
      View in: PubMed
    73. Batki S. Substance abuse and AIDS: the need for mental health services. New Dir Ment Health Serv. 1990; (48):55-67. PMID: 2077391.
      View in: PubMed
    74. Sorensen JL, Guydish J, Costantini M, Batki S. Changes in needle sharing and syringe cleaning among San Francisco drug abusers. N Engl J Med. 1989 Mar 23; 320(12):807. PMID: 2922030.
      View in: PubMed
    75. Sorensen JL, Batki S, Good P, Wilkinson K. Methadone maintenance program for AIDS-affected opiate addicts. J Subst Abuse Treat. 1989; 6(2):87-94. PMID: 2746716.
      View in: PubMed
    76. Batki S, Sorensen JL, Gibson DR, Maude-Griffin P. HIV-infected i.v. drug users in methadone treatment: outcome and psychological correlates--a preliminary report. NIDA Res Monogr. 1989; 95:405-6. PMID: 2641010.
      View in: PubMed
    77. Batki S. Treatment of intravenous drug users with AIDS: the role of methadone maintenance. J Psychoactive Drugs. 1988 Apr-Jun; 20(2):213-6. PMID: 3418453.
      View in: PubMed
    78. Batki S, Sorensen JL, Faltz B, Madover S. Psychiatric aspects of treatment of i.v. drug abusers with AIDS. Hosp Community Psychiatry. 1988 Apr; 39(4):439-41. PMID: 3371914.
      View in: PubMed
    79. Dilley JW, Shelp EE, Batki S. Psychiatric and ethical issues in the care of patients with AIDS. Psychosomatics. 1986 Aug; 27(8):562-6. PMID: 3749429.
      View in: PubMed
    Steven's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP